219 related articles for article (PubMed ID: 35139126)
41. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
43. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
44. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
[TBL] [Abstract][Full Text] [Related]
46. Expression of B7 family checkpoint proteins in cervical cancer.
Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
[TBL] [Abstract][Full Text] [Related]
47. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Jain D; Sukumar S; Mohan A; Iyer VK
Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
[TBL] [Abstract][Full Text] [Related]
48. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
Mezache L; Paniccia B; Nyinawabera A; Nuovo GJ
Mod Pathol; 2015 Dec; 28(12):1594-602. PubMed ID: 26403783
[TBL] [Abstract][Full Text] [Related]
49. PD-1 and PD-L1 expression in rare lung tumors.
Gyulai M; Megyesfalvi Z; Reiniger L; Harko T; Ferencz B; Karsko L; Agocs L; Fillinger J; Dome B; Szallasi Z; Moldvay J
Pathol Oncol Res; 2023; 29():1611164. PubMed ID: 37274772
[No Abstract] [Full Text] [Related]
50. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
51. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
[TBL] [Abstract][Full Text] [Related]
52. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
53. Histopathological Subtypes and PD-L1 Expression in Primary Urethral Adenocarcinoma: A Series of 5 Cases.
Padilla-Ansala C; García-Fernández E; González-Peramato P
Int J Surg Pathol; 2021 Aug; 29(5):488-495. PubMed ID: 33463392
[TBL] [Abstract][Full Text] [Related]
54. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
55. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
56. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
57. Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma.
Iijima M; Okonogi N; Nakajima NI; Morokoshi Y; Kanda H; Yamada T; Kobayashi Y; Banno K; Wakatsuki M; Yamada S; Kamada T; Aoki D; Hasegawa S
J Gynecol Oncol; 2020 Mar; 31(2):e19. PubMed ID: 31912675
[TBL] [Abstract][Full Text] [Related]
58. Expression of Twist enhances risk of poor oncologic outcome in patients with stage Ib to II cervical carcinoma with lymphovascular space involvement.
Kajiyama H; Shibata K; Umezu T; Mizuno M; Suzuki S; Yamamoto E; Fujiwara S; Kikkawa F
Hum Pathol; 2013 Feb; 44(2):181-8. PubMed ID: 22974479
[TBL] [Abstract][Full Text] [Related]
59. Significance of PD-L1 Expression in Tongue Cancer Development.
Yoshida S; Nagatsuka H; Nakano K; Kogashiwa Y; Ebihara Y; Yano M; Yasuda M
Int J Med Sci; 2018; 15(14):1723-1730. PubMed ID: 30588196
[No Abstract] [Full Text] [Related]
60. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
